Atopia Therapeutics names Gregoire Chevalier as CEO
Swiss drug developer Atopia Therapeutics has appointed Dr Grégoire Chevalier as chief executive (CEO).
Formerly known as HpVac, the company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the growing global burden of atopic diseases.
Dr Chevalier brings over 10 years of research and drug development experience to Atopia Therapeutics. He joins the company from Enterome, a leading French biotech focused on innovative immunotherapy for cancer, where he spent the last five years directing several R&D programs. Throughout his career, he has demonstrated a strong ability to drive strategic initiatives and foster a culture of innovation and excellence. He will now lead Atopia’s strategy and development and strengthen the overall organization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze